Getting Truvada to Those That Really Need It The Most

It is not just the poor and uninsured that do not have access to Truvada


Truvada Bone Lawsuit News

Friday, June 28, 2019 - It is not how may dosages of Truvada are made available that counts, although that is important. What matters more is getting Truvada to the demographic that is in the most desperate need of the drug and also teaching them why it is critical that they take it. Unquestionably, that market would be gay, inner-city, teenage black and Latino men. Before I go into the details of why targeting this demographic is so important, there are other cross-currents that need to be addressed. One such issue is asking Gilead why have safer drugs been kept from the consumer when it became known that Truvada is dangerously toxic, substantially contributing to bone density loss called osteoporosis and also contributing to kidney failure and other serious renal problems. While HIV is thought of as a terminal illness, kidney failure and a lifetime of broken, brittle bones is not that much better. HIV prophylactic drug Descovy has been proven to be a safer alternative to Truvada but may have been kept off or the market. Truvada lawyers have seen the aftereffects of numerous drug recalls, and have won significant compensation for the clients.

According to POZ Magazine Online, "The U.S. Food and Drug Administration (FDA) approved Descovy in April 2016 to be used in combination with other antiretrovirals (ARVs) to treat HIV. Research among HIV-positive people has shown that the drug is less toxic to the bones and kidneys than Truvada. The reason is that Descovy contains an updated version of the drug tenofovir, called TAF, while Truvada contains the older take on that drug, TDF. Both tablets also contain emtricitabine." Although bone density may return to normal after using Truvada for a short period of time, it is unknown whether bone regeneration in long term patients will occur. In addition, Such bone density loss may permanently affect skeletal development in younger Truvada patient, exactly the age of those that need the HIV preventive drug the most. " Recent research has also raised the question of whether Truvada as PrEP may stunt bone growth among people in their teens and early twenties whose bones are still growing."

It is not completely clear whether or not Gilead Pharmaceuticals is acting from a sense of moral obligation or self-preservation when it comes to the deal the company recently reached with the Trump administration to provide HIV prophylactic medication Truvada free of charge to those that want to take it. On the surface, it would seem logical that the more people that have access to the drug the more that will get it but that is not necessarily the case. Getting the drug to people that need it the most is much more complicated. 18-22-year-old black and Latino gay men is a demographic in the US where there is a disproportionate number of HIV cases every year and where the spread of the disease is the greatest. The Center for Disease Control reports that "An estimated 1,122,900 people had HIV at the end of 2015. Black/African American gay and bisexual men accounted for 19% (218,600) of all people with HIV and 32% of all gay and bisexual men with HIV. " This particular group of young men needs educational programs as much as free Truvada to effectively fight the disease.

More Recent Truvada Bone Lawsuit News:

No-Cost, No-Obligation Truvada Lawsuit Case Review If You or a Loved One Suffered from Truvada Bone or Kidney Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The firm has represented thousands of persons in these and other products liability litigation, including DePuy hip replacement systems, which settled for $2.5 billion and Pradaxa internal bleeding, which settled for $650 million. The Onder Law Firm won over $300 million in four talcum powder ovarian cancer lawsuits in St. Louis to date and other law firms throughout the nation often seek its experience and expertise on complex litigation.